Treatment specialists

Eye and nerve symptoms can be urgent in IgG4-RD. Learn what eye and brain specialists watch for, together.

Ophthalmologists and neurologists: When IgG4-RD affects eyes and nerves

If IgG4-related disease (IgG4-RD) shows up near your eyes, brain, or cranial or peripheral nerves, it can feel scary fast—because those areas control things you rely on every day: sight, balance, hearing, and facial sensation. The good news is that when ophthalmologists (eye doctors) and neurologists (nerve/brain doctors) team up early, patients get to a diagnosis more quickly, get treated promptly and appropriately, and do much better.

In this lesson, we’ll walk through what each specialist is looking for, what “urgent” symptoms look like, and how cross-specialty care can change the outcome.

The key medical ideas: mass effect and tissue damage

Mass effect is a medical term that means swollen tissue is pressing on something important, like a nerve.

Tissue damage means the inflamed area has been irritated so long that scarring (fibrosis) starts to replace healthy tissue. ^{2, 5}

A helpful picture: think of the eye and nerves as delicate electrical cables running through narrow tunnels. IgG4-RD can cause the tunnel walls to thicken and swell. Even if the “cable” is still intact, pressure can make it stop working well. ^{2, 4, 5}

What an ophthalmologist adds: protecting vision early

When IgG4-RD involves the eye area, doctors often use the term IgG4-related ophthalmic disease (IgG4-ROD)— meaning IgG4-RD affecting the orbit (the eye socket) and nearby structures. A number of critical structures are associated with the orbits:

• The optic nerve, which transports vision signals from the retina to the brain so that we can see.

• Arteries that supply blood to the structures of the orbits.

• A set of muscles (the “extraocular muscles”) that attach to the eyes and permit movement of the eyes in any direction.

• The orbit is packed carefully with fat, which serves to protect the delicate orbital structures.

• The lacrimal glands, which produce tears, sit on the upper outer corner of the eyes, just outside the orbits.

Ophthalmologists pay close attention to:

• Lacrimal glands (tear glands): swelling can look like puffy upper eyelids.⁶

• Eye muscles and soft tissue in the orbit: can cause double vision or the eye to look pushed forward.

• Optic nerve risk: pressure near the back of the orbit (the “orbital apex”) can threaten vision.^6–8

Ophthalmologists also perform careful “function checks,” to make sure the structures within the orbit are working properly, because imaging alone doesn’t tell the whole story:

• vision sharpness, color vision, and side vision testing

• eye movement testing

• a close look at the optic nerve during an eye examination, during which the ophthalmologist uses an instrument known as a slit lamp to peer into the back of the eye.

Why this matters: vision loss can become permanent if the optic nerve is injured for too long—so eye symptoms are not something to “watch and wait” on without a plan.^{6, 8}

What a neurologist adds: the nervous system map

Cranial nerves are the nerves that come directly out of the brain (or, more precisely, out of the brainstem—the neural tissue between the spinal cord and brain. The cranial nerves control vision, hearing, balance, facial feeling, swallowing, and more.

IgG4-RD can affect nervous system structures in a few ways, including:

Hypertrophic pachymeningitis: a medical term for thickened, inflamed dura (the lining around the brain and spinal cord). Inflamed dura can lead to compression of the cranial nerves as they exit the brainstem, impairing cranial nerve function.

Cavernous sinus region involvement: a crowded space behind the eye where multiple cranial nerves and blood vessels run together—so inflammation there can cause double vision, eye pain, facial numbness, or vision changes.

Pituitary gland inflammation (hypophysitis): the pituitary gland, which produces some of the body’s most essential hormones, sits at the base of the brain near near the optic pathways. Inflammation there can cause headaches, hormone problems, and sometimes vision issues if nearby structures are affected.

Neurologists often coordinate MRI interpretation with neuroradiology, and they may recommend spinal fluid testing in select cases—especially when the meninges are involved.^4,10

Patient example: When teamwork changed the plan (and the outcome)

Here’s the kind of cross-specialty story that makes a difference in treating IgG4-RD.

A woman had biopsy-proven IgG4-RD affecting the meninges (hypertrophic pachymeningitis). Over time she developed severe symptoms—headaches, worsening balance and gait, and high risk to vision. Her team tried standard approaches, including peripheral B-cell depletion (rituximab given through the vein), which helped for a while but did not stop slow progression. She became progressively disabled, fell and broke her hip, and after recovery from hip surgery was required to use a walker because her balance was so poor.

Because the disease was still advancing, the team became creative and brought in multiple specialties—including neurology, rheumatology, neurosurgery, and neuro-oncology. They placed a small reservoir under the scalp (an Ommaya reservoir) so medication could be delivered directly into the spinal fluid/ventricular system. This approach to administering medication into the central nervous system is called “intrathecal therapy”. After switching to intrathecal rituximab, the patient experienced dramatic improvement in her neurological function, with restoration of a normal ability to walk.

Watch a video

Barbara’s story: when IgG4-RD affects cranial nerves and the brain lining

Watch this video about Barbara’s case. She describes how sudden hearing loss and balance problems led to the discovery of IgG4-related thickening of the brain’s lining and treatment used to protect her vision.

What “urgent” can look like for eyes and nerves

The following systems are considered urgent, especially if they are new or worsening:

• sudden or fast-worsening vision loss, new double vision, or eye pain^6,8

• new hearing loss, severe dizziness, or major balance change⁴

• severe or persistent headache, especially with neurologic changes^4,10

• new facial numbness/weakness, trouble swallowing, or confusion^9,11

When these symptoms appear, timely specialist evaluation is important, because rapid treatment can limit ongoing inflammation or nerve compression and help prevent lasting damage.^2,6

Treatments: calming inflammation, preventing scarring

Glucocorticoids are a medical term for steroid medicines (such as prednisone or prednisolone). In both ophthalmology and neurology, steroids are often used early because they can reduce inflammation quickly—sometimes within days. That speed matters when IgG4-RD is threatening a structure where delay can lead to lasting loss of function, such as the optic nerve (vision), the cranial nerves that move the eyes (double vision), or the dura/meninges (headache and neurologic deficits).

Ophthalmologists are often watching for improvements in vision testing and optic nerve findings, while neurologists are watching for changes in neurologic exam findings and MRI features of meningeal or skull-base disease. As symptoms stabilize, the shared goal is to taper steroids to the lowest effective dose to reduce long-term risks.²

B-cell depletion is a medical term for medicines that reduce B cells, an immune cell type involved in IgG4-RD. Inebilizumab is an approach to B cell depletion that is approved by regulatory agencies specifically for use in IgG4-RD and is commonly used to treat this condition.

From an ophthalmology standpoint, B cell depletion may be used when orbital inflammation is severe, recurrent, or threatening vision—especially if steroids cannot be reduced without symptoms returning.

From a neurology standpoint, it may be used for serious nervous system involvement such as hypertrophic pachymeningitis or cranial nerve compromise, particularly when the disease is persistent or progressive. In both specialties, the aim is the same: durable control of inflammation while limiting cumulative steroid exposure.^2,3

Two important principles guide the eye–brain team

First, speed matters.

Ophthalmologists worry about a “time window” for the optic nerve. If swelling or compression persists too long, vision loss may not fully reverse even when inflammation is later controlled.

Neurologists worry about the same concept for cranial nerves and the structures at the skull base: persistent inflammation or compression can lead to permanent deficits in eye movement, facial sensation, hearing, or balance.

That’s why these teams often push for prompt imaging, careful function testing (vision fields, eye movements, neurologic exam), and rapid escalation when high-risk structures are involved. ^2,3

Second, fibrosis matters.

Fibrosis means scarring. In IgG4-RD, inflammation can gradually transition into fibrous tissue, and fibrous tissue behaves differently; it is stiffer, less responsive, and harder to reverse.

Ophthalmologists think about this when orbital tissues become firm and restrictive, limiting eye movement or causing persistent double vision.

Neurologists think about it when meningeal thickening becomes more fixed, continuing to irritate or compress nerves even after inflammation quiets down. This is one reason early recognition and effective treatment—before scarring becomes established—can make such a difference in long-term function.^2,3

Summary: the cross-specialty insight

When IgG4-RD involves the orbit, skull base, meninges, or pituitary region, ophthalmologists and neurologists are looking at the same problem from different angles. One is focused on preserving vision and eye function; the other is mapping cranial nerves, brain coverings, and related structures like the pituitary. Together—with rheumatology and radiology—they can move faster, pick safer targets for biopsy, and choose treatments that match the real risk.

References

1. IgG4ward Foundation. Understanding IgG4-related disease (IgG4-RD). IgG4ward.org. (Accessed 2026-02-17). https://igg4ward.org/wp-content/uploads/2025/04/Understanding-IgG4-related-disease_IgG4ward.pdf

2. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539–551. https://pubmed.ncbi.nlm.nih.gov/22316447/

3. Peyronel F, et al. IgG4-related disease: current challenges and future prospects. Nat Rev Rheumatol. 2025. https://pubmed.ncbi.nlm.nih.gov/40195520/

4. Balaban DT, et al. Treatment of IgG4-related disease–associated hypertrophic pachymeningitis with intrathecal rituximab: a case report. Front Neurol. 2023. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1189778/full

5. Stone JH, Zen Y, Deshpande V. Treatment principles and fibrosis impact in IgG4-RD. N Engl J Med. 2012. https://www.nejm.org/doi/abs/10.1056/NEJMra1104650

6. Glass LRD, Freitag SK. Management of orbital IgG4-related disease. Curr Opin Ophthalmol. 2015. https://pubmed.ncbi.nlm.nih.gov/26367090/

7. Chelnis J. IgG4-related Orbital Inflammation. EyeWiki. 2025 update. https://eyewiki.org/IgG4-related_Orbital_Inflammation

8. Tiegs-Heiden CA, et al. Immunoglobulin G4–related disease of the orbit: imaging features. AJNR. 2014. https://pubmed.ncbi.nlm.nih.gov/24627453/

9. Prete A, et al. Hypophysitis (overview, includes IgG4-related causes). NCBI Bookshelf (StatPearls). 2021. https://www.ncbi.nlm.nih.gov/books/NBK519842/

10. Della-Torre E, et al. Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis. J Neurol Neurosurg Psychiatry. 2018;89:441–444.https://pubmed.ncbi.nlm.nih.gov/28819060/

11. Nakata R, et al. IgG4-related disease with cavernous sinus and intraorbital involvement (example of cranial-nerve region disease). [Case report]. 2016. https://pubmed.ncbi.nlm.nih.gov/27580762/

12. Mayeku J, et al. IgG4-related disease of the cavernous sinus with orbit invasion: case report. Surg Neurol Int. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8645509/

13. Liu Y, et al. Hypophyseal involvement in IgG4-related disease (clinical features/outcomes). [Case series]. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5883929/

14. Angelousi A, et al. Hypophysitis (Including IgG4 and Immunotherapy). Neuroendocrinology. 2020. (Includes discussion of IgG4-related hypophysitis; cites endocrine literature including work by Tritos NA in hypophysitis research.) https://pubmed.ncbi.nlm.nih.gov/32126548/

15. Soares C, et al. Intrathecal rituximab in IgG4-hypertrophic pachymeningitis (refractory case example). 2019. https://www.jni-journal.com/article/S0165-5728(19)30193-6/fulltext